Black Diamond Therapeutics vs Fennec Pharmaceuticals
BDTX and FENC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and FENC compare
Fennec Pharmaceuticals is the larger company, worth 5.8 times as much as Black Diamond Therapeutics ($476M against $82.7M).
Fennec Pharmaceuticals grew revenue faster over the last twelve months (77.8% versus −100% for Black Diamond Therapeutics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | FENC |
|---|---|---|
| Size and price | ||
| Market cap | $82.7M | $476M |
| Share price | $1.44 | $13.58 |
| Change, 1 year | −64.1% | 72.8% |
| Change, 5 years | −77.3% | 40.9% |
| Beta (5Y) | 2.12 | 1.89 |
| Employees | 21 | 35 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.0× |
| P/B | 0.9× (better) | 11.2× |
| Fair value | – | $7.22 |
| Margin of safety | – | −88.0% |
| Growth | ||
| Revenue growth (TTM) | −100% | 77.8% (better) |
| Revenue growth, 5Y average | – | 195% |
| Net income growth (TTM) | −395% | – |
| EPS growth (TTM) | −422% | – |
| Profitability | ||
| Operating margin | – | −1.9% |
| Net margin | – | −5.5% |
| Return on equity | −37.2% | −18.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −1.2× |
| Current ratio | 7.28 (better) | 5.85 |
| Altman Z-score | −4.12 | 6.06 (better) |
| Piotroski F-score | 7 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 46.5% |
| Held by insiders | 9.1% | – |
| Insider net buying, 12 months | – | −$9.9M |
| Short interest, % of float | 9.8% | – |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- FENC stock overview
- FENC income statement
- FENC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.